CDEK
← All drugs Report issue

sumatriptan

Trade name: zecuity

Small moleculeapproved

Approved

Dec 28, 1992

Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib). — NCATS

Clinical trial activity

111 trials · 81 clinical orgs · 48 marketing orgs

Phase 1
27
Phase 2
43
Phase 3
32
Phase 4
17

Earliest trial started Aug 1, 1995 (NCT00897104)

Timeline

1990s

  1. Dec 28, 1992

    Earliest FDA Approval

  2. Dec 28, 1992

    GlaxoSmithKline — NDA Secondary Org

  3. Jan 1, 1995

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2003

    Teva — Earliest Phase 1 Sponsor(trial)

  2. Jan 24, 2007

    Mylan — Marketing Organization

  3. Mar 20, 2007

    Roxane Laboratories — Marketing Organization

  4. Mar 20, 2007

    Boehringer Ingelheim — Marketing Organization

  5. Aug 27, 2007

    Chartwell Pharmaceuticals — Marketing Organization

  6. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  7. Apr 15, 2008

    Pernix — Marketing Organization

  8. Apr 15, 2008

    Currax Pharmaceuticals — NDA Secondary Org

  9. Feb 6, 2009

    Sandoz — Marketing Organization

  10. Feb 6, 2009

    West-Ward Pharmaceutical — Marketing Organization

  11. Feb 6, 2009

    Wockhardt — Marketing Organization

  12. Feb 6, 2009

    Novartis — Marketing Organization

  13. Feb 9, 2009

    Teva — Marketing Organization

  14. Mar 2, 2009

    Fresenius — Marketing Organization

  15. Jul 15, 2009

    Endo Pharmaceuticals — NDA Secondary Org

  16. Jul 15, 2009

    Bristol-Myers Squibb — NDA Secondary Org

  17. Aug 10, 2009

    Orbion Pharms — Marketing Organization

  18. Aug 10, 2009

    Aurobindo Pharma — Marketing Organization

  19. Aug 10, 2009

    Fosun — Marketing Organization

  20. Aug 10, 2009

    Orchid Pharma — Marketing Organization

  21. Aug 10, 2009

    Watson Pharmaceuticals — Marketing Organization

  22. Oct 9, 2009

    Par Pharmaceuticals — Marketing Organization

2010s

  1. Jun 10, 2010

    STERISCIENCE — Marketing Organization

  2. Jun 29, 2010

    Meridien Medical Technologies, Inc. — NDA Secondary Org

  3. Jun 29, 2010

    Pfizer — NDA Secondary Org

  4. Aug 11, 2010

    Orofino — Marketing Organization

  5. Aug 11, 2010

    Zydus Discovery DMCC — Marketing Organization

  6. Jan 20, 2011

    Dr. Reddy's Laboratories — NDA Secondary Org

  7. Jun 21, 2011

    Sun Pharmaceuticals — Marketing Organization

  8. Jun 19, 2012

    Apotex — Marketing Organization

  9. Jun 19, 2012

    Corepharma — Marketing Organization

  10. Jun 19, 2012

    Impax Laboratories — Marketing Organization

  11. Jan 17, 2013

    Teva — NDA Secondary Org

  12. Apr 23, 2013

    Eugia Pharma — Marketing Organization

  13. Sep 16, 2013

    Hikma — Marketing Organization

  14. Jan 29, 2014

    Dr. Reddy's Laboratories — Marketing Organization

  15. Dec 10, 2015

    Antares Pharma Inc. — Marketing Organization

  16. Jan 27, 2016

    Avanir — NDA Secondary Org

  17. Jan 28, 2016

    Upsher-Smith Laboratories — Marketing Organization

  18. Jan 28, 2016

    Tonix Pharmaceuticals — Marketing Organization

  19. Jan 28, 2016

    Tonix Pharmaceuticals — NDA Secondary Org

  20. Feb 19, 2016

    Lannett Company, Inc. — Marketing Organization

  21. Sep 4, 2018

    Rising Pharmaceuticals — Marketing Organization

2020s

  1. Sep 21, 2020

    Padagis Us — Marketing Organization

  2. Sep 21, 2020

    Perrigo — Marketing Organization

  3. Feb 17, 2021

    Lachman Consultants — Marketing Organization

  4. Feb 22, 2021

    Cipla — Marketing Organization

  5. Jul 13, 2021

    Caplin Point Laboratories — Marketing Organization

  6. Jul 13, 2021

    Somerset Pharmaceuticals — Marketing Organization

  7. Jan 19, 2023

    Baxalta — Marketing Organization

  8. Jan 19, 2023

    Takeda — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

  • treximet

    with naproxen

    Also known as sumatriptan and naproxen sodium

Approval history

  • approvedPriority reviewDec 28, 1992

Chemistry & pharmacology

Loading structure…

SMILES

CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
Mol. weight
295.41 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • 1-[3-(2-dimethylaminoethyl)-1h-indol-5-yl]-n-methyl-methanesulfonamide
  • 1-[3-(2-dimethylaminoethyl)-1h-indol-5-yl]-n-methyl-methanesulfonamide
  • (3-[2-(dimethylamino)ethyl]-1h-indol-5-yl)-n-methylmethanesulfonamide
  • (3-[2-(dimethylamino)ethyl]-1h-indol-5-yl)-n-methylmethanesulfonamide
  • 3-(2-(dimethylamino)ethyl)-n-methyl-1h-indole-5-methanesulfonamide
  • 3-(2-(dimethylamino)ethyl)-n-methyl-1h-indole-5-methanesulfonamide
  • 3-[2-(dimethylamino)ethyl]-n-methylindole-5-methanesulfonamide
  • 3-[2-(dimethylamino)ethyl]-n-methylindole-5-methanesulfonamide
  • alsuma
  • alsuma
  • dfn-02
  • gr43175
  • gr43175
  • gr43175
  • gr43175
  • gr43175
  • gr43175
  • gr 43175
  • gr-43175c
  • gr-43175c
  • imigran
  • imigran
  • imigran
  • imigran 50
  • imigran radis
  • imigran recovery
  • imigran recovery
  • imigran subject
  • imitrex
  • imitrex
  • imitrex
  • imitrex
  • imitrex statdose
  • imitrex statdose
  • migraitan
  • migraleve ultra
  • np101
  • np101
  • np101
  • prot-cl-np101-015.01
  • sumatran
  • sumatran
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptan
  • sumatriptán
  • sumatriptán
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptan succinate
  • sumatriptanum
  • sumatriptanum
  • sumavel dosepro
  • sumavel dosepro
  • sumax
  • sumax
  • triptan
  • triptan
  • triptan
  • zecuity
  • zecuity

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06563375Phase 1Dec 1, 2024University of Texas at Houston
NCT06217094Phase 1Nov 30, 2024Florida Department of Health, University of Florida
NCT06514040N/ANov 27, 2023Cairo University
NCT05785390Phase 2Feb 22, 2023Novatek Pharmaceuticals
NCT05654298N/AMar 15, 2022Katholieke Universiteit Leuven
NCT05211050N/AFeb 15, 2022University of Copenhagen
NCT05108688Phase 4Nov 15, 2021Ain Shams University
NCT05064488Phase 1Oct 4, 2021Merck KGaA
NCT04690270Early Phase 1 (Phase 1)Jan 4, 2021University of Cambridge
NCT04355845Phase 1May 15, 2020Pfizer
NCT04197349N/ASep 24, 2019Alder Biopharmaceuticals, Lundbeck
NCT03877718Phase 2Feb 1, 2019Charleston Laboratories, Inc
NCT04257851Phase 4Jan 1, 2019Damanhour University
NCT03878784N/ANov 12, 2018University of Copenhagen
NCT04948164Phase 3Aug 1, 2018Capital Medical University, Central South University, Guangzhou Medical University, Jilin University, Kunming Medical University, Nanjing Medical University, Peking University, Qingdao University, Sichuan University, Wenzhou Medical University
NCT03585894N/AAug 1, 2018University of Copenhagen
NCT03881644N/AJul 17, 2018University of Copenhagen
NCT03542357N/AFeb 15, 2018University of Copenhagen
NCT03229798Phase 1Jan 17, 2018Kimberly Clark, Wake Research Associates
NCT03338920Phase 3Nov 2, 2017Avanir
Showing 20 of 111 trials
Page 1 / 6

Organizations

Research & Development (81)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit211432001
University of CopenhagenAcademic/Hospital111122007
NuPathe Inc.For profit8822007
Dr. Reddy's LaboratoriesFor profit6632005
ClinvestFor profit5012009
MerckFor profit5431995
Allergan PLC (2015)For profit4412009
PfizerFor profit4421996
NovartisFor profit3322009
POZENFor profit3312004
TevaFor profit3212003
Alder BiopharmaceuticalsFor profit2122012
AvanirFor profit2212012
Eli LillyFor profit2222008
Kendle International Inc.For profit2012004
MylanFor profit2212004
New York UniversityAcademic/Hospital2212015
OptiNose ASFor profit2222011
Prism ResearchFor profit2012008
RanbaxyFor profit2212008
81 organizations
Page 1 / 5

Marketing (64)

OrganizationOrg typeRelationshipDate
Antares Pharma Inc.For profitMKTGDec 10, 2015
ApotexFor profitMKTGJun 19, 2012
Aurobindo PharmaFor profitMKTGAug 10, 2009
Aurobindo PharmaFor profitSYNApr 23, 2013
AvanirFor profitNDA2Jan 27, 2016
BaxaltaFor profitMKTGJan 19, 2023
Boehringer IngelheimFor profitMKTGMar 20, 2007
Bristol-Myers SquibbFor profitNDA2Jul 15, 2009
Caplin Point LaboratoriesFor profitMKTGJul 13, 2021
Chartwell PharmaceuticalsFor profitMKTGAug 27, 2007
CiplaFor profitMKTGFeb 22, 2021
CorepharmaFor profitMKTGJun 19, 2012
Currax PharmaceuticalsFor profitNDA2Apr 15, 2008
Dr. Reddy's LaboratoriesFor profitNDA2Jan 20, 2011
Dr. Reddy's LaboratoriesFor profitSYNAug 10, 2009
Dr. Reddy's LaboratoriesFor profitMKTGJan 29, 2014
Endo PharmaceuticalsFor profitNDA2Jul 15, 2009
Eugia PharmaFor profitMKTGApr 23, 2013
FosunFor profitMKTGAug 10, 2009
FreseniusFor profitMKTGMar 2, 2009
GlaxoFor profitNDA—
GlaxoSmithKlineFor profitNDA2Dec 28, 1992
HikmaFor profitMKTGSep 16, 2013
HikmaFor profitSYNMay 21, 2013
Impax LaboratoriesFor profitMKTGJun 19, 2012
Lachman ConsultantsFor profitMKTGFeb 17, 2021
Lannett Company, Inc.For profitMKTGFeb 19, 2016
Meridien Medical Technologies, Inc.For profitNDA2Jun 29, 2010
MylanFor profitMKTGJan 24, 2007
MylanFor profitSYNJun 10, 2010
MylanFor profitSYNApr 14, 2014
MylanFor profitSYNSep 4, 2018
NovartisFor profitMKTGFeb 6, 2009
Orbion PharmsFor profitMKTGAug 10, 2009
Orchid PharmaFor profitMKTGAug 10, 2009
OrofinoFor profitMKTGAug 11, 2010
Padagis UsFor profitMKTGSep 21, 2020
Par PharmaceuticalsFor profitMKTGOct 9, 2009
Par PharmaceuticalsFor profitSYNJul 9, 2009
PernixFor profitMKTGApr 15, 2008
PerrigoFor profitMKTGSep 21, 2020
PfizerFor profitNDA2Jun 29, 2010
Rising PharmaceuticalsFor profitMKTGSep 4, 2018
Roxane LaboratoriesFor profitMKTGMar 20, 2007
STERISCIENCEFor profitMKTGJun 10, 2010
SandozFor profitMKTGFeb 6, 2009
SandozFor profitSYNFeb 6, 2009
Somerset PharmaceuticalsFor profitMKTGJul 13, 2021
Sun PharmaceuticalsFor profitMKTGJun 21, 2011
Sun PharmaceuticalsFor profitSYNAug 10, 2009
Sun PharmaceuticalsFor profitSYNFeb 9, 2009
Sun PharmaceuticalsFor profitSYNJun 21, 2011
TakedaFor profitMKTGJan 19, 2023
TevaFor profitNDA2Jan 17, 2013
TevaFor profitMKTGFeb 9, 2009
TevaFor profitSYNJul 29, 2008
TevaFor profitSYNFeb 6, 2009
Tonix PharmaceuticalsFor profitMKTGJan 28, 2016
Tonix PharmaceuticalsFor profitNDA2Jan 28, 2016
Upsher-Smith LaboratoriesFor profitMKTGJan 28, 2016
Watson PharmaceuticalsFor profitMKTGAug 10, 2009
West-Ward PharmaceuticalFor profitMKTGFeb 6, 2009
WockhardtFor profitMKTGFeb 6, 2009
Zydus Discovery DMCCFor profitMKTGAug 11, 2010